Novo Nordisk Debt to Equity Ratio 2006-2018 | NVO

Current and historical debt to equity ratio values for Novo Nordisk (NVO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Novo Nordisk debt/equity for the three months ending September 30, 2018 was 0.00.
Novo Nordisk Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $0.00B $7.41B 0.00
2018-06-30 $0.00B $7.86B 0.00
2018-03-31 $0.00B $7.30B 0.00
2017-12-31 $0.00B $7.57B 0.00
2017-09-30 $0.00B $7.42B 0.00
2017-06-30 $0.00B $7.16B 0.00
2017-03-31 $0.00B $5.78B 0.00
2016-12-31 $0.00B $6.73B 0.00
2016-09-30 $0.00B $6.20B 0.00
2016-06-30 $0.00B $6.47B 0.00
2016-03-31 $0.00B $5.51B 0.00
2015-12-31 $0.00B $6.99B 0.00
2015-09-30 $0.00B $6.43B 0.00
2015-06-30 $0.00B $5.80B 0.00
2015-03-31 $0.00B $4.87B 0.00
2014-12-31 $0.00B $7.18B 0.00
2014-09-30 $0.00B $6.76B 0.00
2014-06-30 $0.00B $6.74B 0.00
2014-03-31 $0.00B $6.17B 0.00
2013-12-31 $0.00B $7.58B 0.00
2013-09-30 $0.00B $6.95B 0.00
2013-06-30 $0.00B $6.20B 0.00
2013-03-31 $0.00B $5.99B 0.00
2012-12-31 $0.00B $7.02B 0.00
2012-09-30 $0.09B $5.99B 0.01
2012-06-30 $0.09B $5.42B 0.02
2012-03-31 $0.09B $5.71B 0.02
2011-12-31 $0.09B $7.00B 0.01
2011-09-30 $0.10B $6.73B 0.01
2011-06-30 $0.10B $7.13B 0.01
2011-03-31 $0.09B $6.38B 0.01
2010-12-31 $0.09B $6.59B 0.01
2010-09-30 $0.17B $5.93B 0.03
2010-06-30 $0.17B $5.75B 0.03
2010-03-31 $0.18B $6.12B 0.03
2009-12-31 $0.18B $6.69B 0.03
2009-09-30 $0.19B $6.70B 0.03
2009-06-30 $0.18B $6.23B 0.03
2009-03-31 $0.18B $5.49B 0.03
2008-12-31 $0.19B $6.50B 0.03
2008-09-30 $0.20B $6.50B 0.03
2008-06-30 $0.20B $6.94B 0.03
2008-03-31 $0.19B $6.28B 0.03
2007-12-31 $0.18B $5.92B 0.03
2007-09-30 $0.21B $6.14B 0.03
2007-06-30 $0.21B $6.06B 0.04
2007-03-31 $0.21B $5.22B 0.04
2006-12-31 $0.20B $5.06B 0.04
2006-09-30 $0.20B $4.84B 0.04
2006-06-30 $0.20B $4.86B 0.04
2006-03-31 $0.20B $4.35B 0.05
2005-12-31 $0.21B $4.62B 0.05
2005-09-30 $0.21B $4.30B 0.05
2005-06-30 $0.21B $4.15B 0.05
2005-03-31 $0.22B $4.47B 0.05
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $109.812B $16.962B
Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural resources.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $389.933B 18.28
Pfizer (PFE) United States $263.593B 14.86
Novartis AG (NVS) Switzerland $206.763B 17.67
Merck (MRK) United States $201.837B 17.49
AbbVie (ABBV) United States $133.559B 11.85
Eli Lilly (LLY) United States $118.867B 20.90
Sanofi (SNY) France $114.344B 14.16
AstraZeneca (AZN) United Kingdom $103.773B 12.88
GlaxoSmithKline (GSK) United Kingdom $102.421B 13.77
Bristol-Myers Squibb (BMY) United States $87.143B 14.35